CN104086541A - Pharmaceutical composition for treating respiratory tract infections of children - Google Patents
Pharmaceutical composition for treating respiratory tract infections of children Download PDFInfo
- Publication number
- CN104086541A CN104086541A CN201410345932.XA CN201410345932A CN104086541A CN 104086541 A CN104086541 A CN 104086541A CN 201410345932 A CN201410345932 A CN 201410345932A CN 104086541 A CN104086541 A CN 104086541A
- Authority
- CN
- China
- Prior art keywords
- respiratory tract
- pharmaceutical composition
- tract infection
- compound
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
The invention relates to a pharmaceutical composition for treating respiratory tract infections of children. The pharmaceutical composition is characterized by comprising a compound in an effective amount and a pharmaceutically acceptable carrier; the compound has the structure as shown in the specification. The compound has obvious effect on the pathogenic bacteria of the respiratory tract infections of children and can be developed into a clinically effective new pharmaceutical composition.
Description
Technical field
The present invention relates to field of medicaments, specifically, the present invention relates to a kind of pharmaceutical composition for the treatment of infantile respiratory tract infection.
Background technology
Infantile respiratory tract infection repeatedly is common clinical frequently-occurring disease, RRTI is a kind of common disease, the frequently-occurring disease of paying attention to gradually for Chinese scholars in recent years, modern medicine thinks that definite pathogenesis still imperfectly understands, be the result of many factors comprehensive action, immunologic hypofunction is considered to one of major reason of morbidity.
Recurrent respiratory tract infection (RRTI) Case definition according in April, 1987 whole nation infantile respiratory disease academic conference revision: 0～2 years old age, 7 times/year of upper respiratory tract infection, 3 times/year of lower respiratory infections; 3～5 years old age, 6 times/year of upper respiratory tract infection, 2 times/year of lower respiratory infections; 6～14 years old age, 5 times/year of upper respiratory tract infection, 2 times/year of lower respiratory infections.The 2nd distance of upper respiratory tract infection the 1st time is more than at least 7 days.If upper respiratory tract infection number of times is inadequate, can adds lower respiratory infection number of times, otherwise not become.Respiratory tract infection is one of modal disease of children's, is especially more common in winter-spring season.The treatment of modern medicine to susceptible, how from zinc supplementation, replenish the calcium, vitimin supplement, gamma-globulin, Zadaxin, transfer factor etc., to improve infant immunizing power.But indivedual physique is lacked to immunotherapy targeted autoantibody, and effect is not ideal enough.
Find after deliberation, in the children's's of respiratory tract infection saliva, various pathogens detected, wherein Klebsiella Pneumoniae and enterobacter cloacae are exactly most typical two kinds.
Summary of the invention
The object of the present invention is to provide a kind of pharmaceutical composition for the treatment of infantile respiratory tract infection.
In order to realize object of the present invention, the invention provides a kind of compound for the treatment of infantile respiratory tract infection, this compound has lower array structure:
The present invention also provides a kind of pharmaceutical composition for the treatment of infantile respiratory tract infection, the compound that described pharmaceutical composition comprises significant quantity and pharmaceutically acceptable carrier, and described compound has lower array structure:
Preferably, described pharmaceutically acceptable carrier is thinner, disintegrating agent, tackiness agent, lubricant, stablizer or corrigent.
Preferably, described thinner is sugar derivatives, starch derivative or derivatived cellulose.
Preferably, described thinner is lactose.
Preferably, described pharmaceutical composition is powder, microgranules, granule, capsule or tablet.
The present invention also provides the purposes of compound in the medicine of preparation treatment infantile respiratory tract infection, and this compound has lower array structure:
Preferably, described infantile respiratory tract infection is caused by Klebsiella Pneumoniae ATCC4352.
Term used herein " pharmaceutically acceptable " refers to the material of biologic activity or the character of not eliminating compound as herein described, as carrier or thinner.This class material is applied to and individual does not cause undesirable biological action or not to be harmful to any component interaction in mode and the composition that comprises it.
Term " pharmaceutically acceptable carrier " comprises any and all solvents as used herein, dispersion medium, coating material, tensio-active agent, antioxidant, sanitas (for example antiseptic-germicide, anti-mycotic agent), isotonic agent, absorption delay agent, salt, sanitas, medicine stablizer, tackiness agent, vehicle, disintegrating agent, lubricant, sweeting agent, correctives, dyestuff etc. and its combination, this is well-known to those skilled in the art (for example, referring to Remington's Pharmaceutical Sciences, 18th Ed.Mack Printing Company, 1990, pp.1289-1329).Except with the inconsistent carrier of activeconstituents, treatment or pharmaceutical composition in consider use any conventional carrier.
Compound of the present invention is remarkable for the pathogenic bacteria effect that causes infantile respiratory tract infection, can be developed to clinically effectively new pharmaceutical composition.
Embodiment
Below the invention will be further described for the description by embodiment, but this is not limitation of the present invention, those skilled in the art are according to basic thought of the present invention, can make various amendments or improvement, but only otherwise depart from basic thought of the present invention, all within the scope of the present invention.
Experimental example the compounds of this invention causes the research of the purposes in the medicine of Klebsiella Pneumoniae of infantile respiratory tract infection in preparation vitro inhibition
Bacteriostatic test
Use following compounds, adopt filter paper method classical in this area to carry out bacteriostatic test, wherein:
The structural formula of compound is:
For examination bacterial classification
Klebsiella Pneumoniae ATCC4352 is purchased from Bei Nuo bio tech ltd, Shanghai.
Nutrient solution
Nutrient agar medium and nutrient broth, purchased from Chen Yu experimental installation company limited of BeiJing ZhongKe.
Test method
Klebsiella Pneumoniae ATCC4352 is inoculated in agar plate nutritive medium plane, when inoculation, evenly gathers.
Take 0.2 gram of target compound, add 5000 ml sterile waters, ultrasonic 30 minutes, then the filtering with microporous membrane of 0.22 μ m, obtained solution.The aseptic circular filter paper sheet of tweezer, sprays above-mentioned solution to complete wetting, is attached in the agar plate nutritive medium plane of inoculated bacteria.Agar plate is placed in the incubator of 37 DEG C to incubation 4 hours.Measure the diameter of antibacterial ring.Measure and average for 3 times.
1.4 result
The mean diameter of the antibacterial ring of Klebsiella Pneumoniae ATCC4352 is 13.82mm, and this shows that target compound has the effect of extremely strong inhibition Klebsiella Pneumoniae ATCC4352.
Claims (8)
1. a compound for the treatment of infantile respiratory tract infection, is characterized in that, this compound has lower array structure:
2. a pharmaceutical composition for the treatment of infantile respiratory tract infection, is characterized in that, the compound that described pharmaceutical composition comprises significant quantity and pharmaceutically acceptable carrier, and described compound has lower array structure:
3. the pharmaceutical composition for the treatment of infantile respiratory tract infection according to claim 2, is characterized in that, described pharmaceutically acceptable carrier is thinner, disintegrating agent, tackiness agent, lubricant, stablizer or corrigent.
4. the pharmaceutical composition for the treatment of infantile respiratory tract infection according to claim 3, is characterized in that, described thinner is sugar derivatives, starch derivative or derivatived cellulose.
5. the pharmaceutical composition for the treatment of infantile respiratory tract infection according to claim 4, is characterized in that, described thinner is lactose.
6. the pharmaceutical composition for the treatment of infantile respiratory tract infection according to claim 3, is characterized in that, described pharmaceutical composition is powder, microgranules, granule, capsule or tablet.
7. the purposes of compound in the medicine of preparation treatment infantile respiratory tract infection, is characterized in that, this compound has lower array structure:
8. purposes according to claim 7, is characterized in that, described infantile respiratory tract infection is caused by Klebsiella Pneumoniae ATCC4352.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410345932.XA CN104086541B (en) | 2014-07-18 | 2014-07-18 | A kind of pharmaceutical composition for the treatment of infantile respiratory tract infection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410345932.XA CN104086541B (en) | 2014-07-18 | 2014-07-18 | A kind of pharmaceutical composition for the treatment of infantile respiratory tract infection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104086541A true CN104086541A (en) | 2014-10-08 |
| CN104086541B CN104086541B (en) | 2016-01-20 |
Family
ID=51634329
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410345932.XA Expired - Fee Related CN104086541B (en) | 2014-07-18 | 2014-07-18 | A kind of pharmaceutical composition for the treatment of infantile respiratory tract infection |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104086541B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105218465A (en) * | 2015-11-14 | 2016-01-06 | 刘杰 | A kind of pharmaceutical composition for the treatment of mammary cancer |
| CN105687189A (en) * | 2016-03-08 | 2016-06-22 | 高芳 | Medicine composition for treating upper respiratory tract infection |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1066729C (en) * | 1995-06-01 | 2001-06-06 | 三共株式会社 | Benzimidazole derivatives, their preparation and their therapeutic use |
| CN102250082A (en) * | 2011-05-05 | 2011-11-23 | 中国人民解放军第四军医大学 | Benzimidazolyl thiazolidinone compounds and synthesis method thereof |
| CN104083364A (en) * | 2014-07-18 | 2014-10-08 | 任荣源 | Pharmaceutical composition for treating children respiratory tract infection caused by enterobacter cloacae |
-
2014
- 2014-07-18 CN CN201410345932.XA patent/CN104086541B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1066729C (en) * | 1995-06-01 | 2001-06-06 | 三共株式会社 | Benzimidazole derivatives, their preparation and their therapeutic use |
| CN102250082A (en) * | 2011-05-05 | 2011-11-23 | 中国人民解放军第四军医大学 | Benzimidazolyl thiazolidinone compounds and synthesis method thereof |
| CN104083364A (en) * | 2014-07-18 | 2014-10-08 | 任荣源 | Pharmaceutical composition for treating children respiratory tract infection caused by enterobacter cloacae |
Non-Patent Citations (2)
| Title |
|---|
| AGNÈS COSTE，等: "PPARγ Promotes Mannose Receptor Gene Expression in Murine Macrophages and Contributes to the Induction of This Receptor by IL-13", 《IMMUNITY》 * |
| 杨中卫，等: "PPAR-γ信号通路在呼吸道疾病中的作用", 《医学综述》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105218465A (en) * | 2015-11-14 | 2016-01-06 | 刘杰 | A kind of pharmaceutical composition for the treatment of mammary cancer |
| CN105687189A (en) * | 2016-03-08 | 2016-06-22 | 高芳 | Medicine composition for treating upper respiratory tract infection |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104086541B (en) | 2016-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104083364B (en) | A kind of pharmaceutical composition for the treatment of the infantile respiratory tract infection that enterobacter cloacae causes | |
| CN105287790A (en) | Paederia scandens extract and applications thereof | |
| CN104086541B (en) | A kind of pharmaceutical composition for the treatment of infantile respiratory tract infection | |
| CN105198903A (en) | Pharmaceutical composition for treating acute upper respiratory infection | |
| CN105085503A (en) | Medicine composition for treating respiratory tract infection | |
| CN113967243B (en) | Fermented traditional Chinese medicine preparation for preventing and treating diarrhea of poultry and preparation method thereof | |
| RU2297842C2 (en) | Method for animal mycotoxicosis prophylaxis | |
| CN115651860A (en) | Bacillus coagulans BC-HYC strain and application thereof | |
| CN105237542A (en) | Medicine composition for treating gynecological diseases | |
| CN102416050B (en) | Veterinary medicinal preparation for treating colibacillosis and preparation method thereof | |
| CN105061331A (en) | Pharmaceutical composition for eliminating phlegm for children | |
| CN105294535A (en) | Pharmaceutical composition used for treating pelvic inflammation | |
| CN105412076B (en) | Compound purposes in the medicine of preparation treatment infantile diarrhea | |
| CN106987543B (en) | A kind of serratia marcescens BSFL-6 in stratiomyiid enteron aisle source and its application | |
| CN105348183A (en) | Pharmaceutical composition for treating gynecology-and-obstetrics postoperative low-fever symptom | |
| CN111821322A (en) | Poultry micro-ecological oral preparation capable of replacing antibiotics and application thereof | |
| CN105232542B (en) | A kind of pharmaceutical composition for the treatment of infantile pneumonia | |
| CN105232504B (en) | A kind of pharmaceutical composition for the treatment of infantile respiratory tract infection repeatedly | |
| CN105111185A (en) | Pharmaceutical composition for treating vaginitis of elder people | |
| CN105218460A (en) | A kind of pharmaceutical composition for the treatment of enteritis | |
| CN105748477B (en) | A kind of medicine treating infantile enteritiss | |
| CN110946990B (en) | Respiratory tract microecological spray preparation for poultry and application thereof | |
| CN105622619A (en) | Medicine composition for treating periodontitis | |
| CN105254477A (en) | Medicine composition for treatment of vaginitis | |
| CN105232540A (en) | Drug combination for treating infection after burn |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| CB03 | Change of inventor or designer information |
Inventor after: Gao Zhongshe Inventor after: Wang Mingming Inventor after: Shao Yanshi Inventor before: The inventor has waived the right to be mentioned |
|
| COR | Change of bibliographic data | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20151214 Address after: Derek street in Jimo City, Shandong province 266000 Qingdao City No. 4 Applicant after: Gao Zhongshe Address before: 100730 Beijing city Shuaifuyuan Dongcheng District No. 1 Peking Union Medical College Hospital Applicant before: Ren Rongyuan |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160120 Termination date: 20160718 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |